FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
Go back to FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 9.94 -0.12 (1.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.06 | 52 Week High | $2.18 | |||
| Open | $10.00 | 52 Week Low | $0.30 | |||
| Day High | $10.01 | P/E | N/A | |||
| Day Low | $9.79 | EPS | $-3.32 | |||
| Volume | 56,412 | |||||
